Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 22:13:1089944.
doi: 10.3389/fonc.2023.1089944. eCollection 2023.

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments

Chiara Piubelli  1 , Matteo Valerio  2 , Matteo Verzè  3 , Fabrizio Nicolis  3 , Carlotta Mantoan  4 , Sonia Zamboni  2 , Francesca Perandin  1 , Eleonora Rizzi  1 , Stefano Tais  1 , Monica Degani  1 , Sara Caldrer  1 , Federico Giovanni Gobbi  1 , Zeno Bisoffi  1 , Stefania Gori  2
Affiliations

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments

Chiara Piubelli et al. Front Oncol. .

Abstract

Introduction: Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatment. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose.

Methods: In our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies.

Results and discussion: Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.

Keywords: Comirnaty; IgG; SARS-CoV-2; anticancer treatment; metastasis; neutralizing antibodies; solid tumors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of tumor type and treatment at different time point. Charts (A–D) refer respectively to T1 and T2. (GI, Gastrointestinal; GU, Genitourinary; C, Chemotherapy; H, Hormone therapy; I, Immunotherapy; T, Target therapy; No, No treatment).
Figure 2
Figure 2
Distribution of the IgG-RBD-S value, expressed in BAU/mL, across groups. Box plots (A–D) refer respectively to T1 and T2. Each box covers the interquartile range; the splitting line is the median and whiskers represent minimum and maximum values. Statistical significance, set at p-value <0.05, was assessed using the Kruskal-Wallis test. (GI, Gastrointestinal; GU, Genitourinary; C, Chemotherapy; H, Hormone therapy; I, Immunotherapy; T, Target therapy; No, No treatment).
Figure 3
Figure 3
Distribution of the increment in IgG-RBD-S value (IgG-RBD-ST2 - IgG-RBD-ST1), expressed in BAU/mL, across groups for different characteristics. (A: Age, B: Tumor type, C: presence of metastatic disease, D: type of treatment) Each box covers the interquartile range; the splitting line is the median and whiskers represent minimum and maximum values. Statistical significance, set at p-value <0.05, was assessed using the Mann-Whitney U test or the Kruskal-Wallis test. (G, Gastrointestinal; GU, Genitourinary; C, Chemotherapy; H, Hormone therapy; I, Immunotherapy; T, Target therapy; No, No treatment).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Guarneri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, et al. . Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the veneto oncology network: The rete oncologica veneta covID19 study. Eur J Cancer Oxf Engl 1990. (2021) 147:120–7. doi: 10.1016/j.ejca.2021.01.021 - DOI - PMC - PubMed
    1. Dieci MV, Azzarello G, Zagonel V, Bassan F, Gori S, Aprile G, et al. . Clinical profile and mortality of sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-sep 2020; sep 2020-may 2021) in the veneto oncology network: The ROVID study. Eur J Cancer Oxf Engl 1990. (2022) 167:81–91. doi: 10.1016/j.ejca.2022.03.005 - DOI - PMC - PubMed
    1. Italian Ministry of Health . Vaccinazione anti SARS-CoV2/COVID-19. estensione dell’intervallo tra le due dosi dei vaccini a mRNA (2021). Available at: https://www.trovanorme.salute.gov.it/norme/render-NormsanPdf?anno=2021&c....
    1. Italian Ministry of Health . Trasmissione parere del CTS in merito alla estensione dell’intervallo tra le due dosi dei vaccini a mRNA e alla seconda dose del vaccino vaxzevria (2021). Available at: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&co....
    1. Italian Ministry of Health . Aggiornamento parere CTS vaccini (2021). Available at: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&co....